E
RARE icon

Ergoteles’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ergoteles’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-26,662
Closed -$1.23M – 655
2023
Q2 		$1.23M Sell
26,662
-15,182
-36% -$704K 0.06% 407
2023
Q1 		$1.68M Buy
41,844
+18,162
+77% +$779K 0.07% 331
2022
Q4 		$1.1M Sell
23,682
-99,507
-81% -$3.91M 0.04% 441
2022
Q3 		$5.1M Buy
+123,189
New +$6.33M 0.18% 113
2022
Q2 		– Sell
-12,294
Closed -$893K – 1934
2022
Q1 		$893K Sell
12,294
-296
-2% -$20.6K 0.03% 472
2021
Q4 		$1.06M Sell
12,590
-115,510
-90% -$9.4M 0.04% 404
2021
Q3 		$11.6M Sell
128,100
-27,764
-18% -$2.51M 0.42% 56
2021
Q2 		$14.9M Buy
155,864
+146,264
+1,524% +$15.2M 0.34% 69
2021
Q1 		$1.09M Buy
+9,600
New +$1.31M 0.03% 354

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Ergoteles's RARE Position: Q3 2023 in Review

Ergoteles sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2023, closing a stake of 26,662 shares — an estimated $1.23M sold.

Ergoteles first reported a position in RARE in Q1 2021 and held it in 9 quarters. The position peaked at $14.9M in Q2 2021. 219 funds tracked by Wall St. Rank hold RARE as of Q3 2023.

  • Ergoteles reported no remaining Ultragenyx Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 26,662 Ultragenyx Pharmaceutical shares in Q3 2023, an estimated $1.23M.
  • Ergoteles first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 9 quarters.
  • Ergoteles's Ultragenyx Pharmaceutical position peaked at $14.9M in Q2 2021.
  • 219 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.